Vectura signs deal with Novartis for generic U.S. lung therapy

Reuters, 28 June 2017
Authors: Esha Vaish and Martina D’Couto
“Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market. British drugmaker Vectura has been trying to build a specialized lung drug business since it merged with Skypeharma last year. However, the firm hasn’t had it easy, following delays in its generic drug with Hikma coming onto the market, a royalties row with GSK, and delays in Novartis launching its Ultibro inhaler in the U.S. The therapy, which is expected to seek regulatory approval and then be launched in the early to mid-2020.”
Find article here.